Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05954871
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Christiana Care Health System, Newark, Delaware, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 19
- Registration Number
- NCT05930938
- Locations
- 🇫🇷
Hôpital Nord Franche Compté, Montbéliard, France
Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-20
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hummingbird Bioscience
- Target Recruit Count
- 98
- Registration Number
- NCT05910827
- Locations
- 🇲🇩
The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit, Chisinau, Moldova, Republic of
🇦🇺GenesisCare North Shore, Sydney, New South Wales, Australia
🇦🇺ICON Cancer Centre South Brisbane, Brisbane, Queensland, Australia
Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05873972
- Locations
- 🇨🇳
Zhongshan hosptial, Fudan University, Shanghai, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 408
- Registration Number
- NCT05863195
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 15
- Registration Number
- NCT05816785
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT05799443
Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05774964
- Locations
- 🇨🇳
Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 24
- Registration Number
- NCT05775900
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05756153
- Locations
- 🇮🇹
IRCCS Centro di Riferimento Oncologico, Aviano, Friuli-Venezia Giulia, Italy
🇪🇸Virgen del Rocio University Hospital, Sevilla, Spain
🇪🇸Hospital Regional Universitario de Malaga,Oncology Dept, Málaga, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.